Tempest Therapeutics is a development-stage biotechnology company advancing small molecules that modulate anti-tumor immunity pathways. The Company has a balanced and deep pipeline consisting of first-in-class and potential best-in-class small molecule therapeutics that modulate distinct immune response pathways relevant to mounting an effective anti-tumor response.
|HQ||San Francisco, CA, US||Map|
|Employees (est.) (Sept 2021)||17|
Tempest Therapeutics total Funding
Tempest Therapeutics latest funding size
Time since last funding
|3 years ago|
Tempest Therapeutics investors
|Versant Ventures, Foresite Capital, F-Prime Capital Partners, Eight Roads Ventures, Lilly Asia Ventures, Quan Capital|
Who are Tempest Therapeutics key executives?
Tempest Therapeutics's key executives are Stephen Brady, Sam Whiting and Tom Dubensky.
How many employees does Tempest Therapeutics have?
Tempest Therapeutics has 17 employees.
Who are Tempest Therapeutics competitors?
Competitors of Tempest Therapeutics include Leinco Technologies, Riverside Clinical Research and Lineage Cell Therapeutics.
Where is Tempest Therapeutics headquarters?
Tempest Therapeutics headquarters is located at One Sansome Street, 1 Sansome St #3690, San Francisco, San Francisco.
Where are Tempest Therapeutics offices?
Tempest Therapeutics has offices in San Francisco and South San Francisco.
How many offices does Tempest Therapeutics have?
Tempest Therapeutics has 2 offices.
Receive alerts for 300+ data fields across thousands of companies